A novel antibody against cancer stem cell biomarker, DCLK1-S, is potentially useful for assessing colon cancer risk after screening colonoscopy.
about
FOXD3 Regulates CSC Marker, DCLK1-S, and Invasive Potential: Prognostic Implications in Colon Cancer.ReMAPping the microtubule landscape: How phosphorylation dictates the activities of microtubule-associated proteins.DCLK1 Expression in Colorectal Polyps Increases with the Severity of Dysplasia.Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells.Analysis of the clinical significance of DCLK1 colorectal cancer using novel monoclonal antibodies against DCLK1
P2860
A novel antibody against cancer stem cell biomarker, DCLK1-S, is potentially useful for assessing colon cancer risk after screening colonoscopy.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
A novel antibody against cance ...... k after screening colonoscopy.
@en
type
label
A novel antibody against cance ...... k after screening colonoscopy.
@en
prefLabel
A novel antibody against cance ...... k after screening colonoscopy.
@en
P2093
P2860
P1476
A novel antibody against cance ...... k after screening colonoscopy.
@en
P2093
Brian S Lee
Gurinder K Luthra
Heather L Stevenson
Malaney R O'Connell
Pomila Singh
Robert A Obeid
Shubhashish Sarkar
Vsevolod L Popov
P2860
P2888
P304
P356
10.1038/LABINVEST.2017.40
P577
2017-04-17T00:00:00Z
P6179
1084861054